Market Capitalization

CN Energy Group is again facing delisting from Nasdaq. A look beyond the notice reveals a history of compliance struggles and a fractured business model.

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

An institutional investor’s decisive move spotlights a €205M valuation gap in the Addiko Bank takeover, raising critical questions about M&A fairness.

Uniting two Texas title giants, Stewart's acquisition of Rattikin leverages deep historical ties to dominate the booming North Texas real estate landscape.

Intuit faces a class-action lawsuit after a 20% stock drop. Allegations of misleading statements and $41M in insider sales put a spotlight on executive accountability.

CenterPoint Energy’s latest dividend increase isn't just a number. It's a signal of a high-stakes bet on data centers, growth, and financial leverage.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

A Chinese firm aims to revolutionize cancer treatment with a cloud-based AI system, but faces a tough fight against industry giants and its own financial reality.

Entegris's latest dividend is more than a payout; it's a signal of deep financial health and strategic positioning in the critical semiconductor industry.

Rubico Inc. is selling its luxury megayacht to double down on oil tankers. A look at whether this strategic pivot can overcome a history of investor doubt.

A small firm aims to build the first US uranium mill in 40 years, pitting national energy security and AI's power needs against a legacy of environmental risk.

A small U.S. med-tech firm is targeting China's massive cervical cancer screening market. Can its innovative device navigate the regulatory maze for a huge payoff?

Real estate tech firm Linkhome Holdings pivots hard into AI infrastructure with its OpenLink platform, backed by a new $10.5M contract that dwarfs its market cap.

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

The payment giant says operations are normal and refuses to pay hackers. But with business data and transaction records stolen, what is the true cost of defiance?

A class action lawsuit against Roblox is more than a legal battle. It signals the end of the digital economy's growth-at-all-costs era.

Commodities giant Glencore transforms a $25M loan into a major equity position in Osisko Metals, signaling a strong bet on Canadian critical minerals.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

With cash dwindling, Workhorse brings in capital-raising specialist Jody Davis. Can a new financial architect secure the future for this EV hopeful?

Voyager Technologies' acquisition of Astrobotic was no accident. A new $298M NASA contract, secured just in time, reveals a masterstroke in the race for the Moon.